文献速递关节外科

全膝关节置换术后预防静脉血栓栓塞的药物预防方案比较有效性与安全性

Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2017-05-31

基于美国全关节置换登记系统2006年5月16日至2013年12月31日期间30499例单侧全膝关节置换患者数据,比较阿司匹林、低分子肝素、合成五糖Xa因子抑制剂和维生素K拮抗剂预防静脉血栓栓塞的有效性与安全性。未发现磺达肝癸钠、依诺肝素或华法林在预防肺栓塞、深静脉血栓或静脉血栓栓塞方面优于阿司匹林,也未发现阿司匹林比这些替代方案更安全;但依诺肝素在出血方面与阿司匹林安全性相当,磺达肝癸钠在伤口并发症风险方面与阿司匹林安全性相当。

要点

  • 未发现磺达肝癸钠、依诺肝素或华法林在预防肺栓塞、深静脉血栓或静脉血栓栓塞方面优于阿司匹林。
  • 未发现阿司匹林在安全性方面优于磺达肝癸钠、依诺肝素或华法林。
  • 依诺肝素在出血方面与阿司匹林安全性相当,磺达肝癸钠在伤口并发症风险方面与阿司匹林安全性相当。

核心结论

  • 在全膝关节置换患者中,未发现使用阿司匹林降低有效性或增加安全性的证据。
  • 依诺肝素在出血方面与阿司匹林安全性相当,磺达肝癸钠在伤口并发症方面与阿司匹林安全性相当。

研究设计与样本

  • 数据来自美国全关节置换登记系统,纳入2006年5月16日至2013年12月31日期间接受单侧全膝关节置换的30499例患者。
  • 患者接受阿司匹林(每日324-325 mg)、依诺肝素(每日40-60 mg)、磺达肝癸钠(每日2.5 mg)或华法林(所有剂量),术后随访90天,评估深静脉血栓、肺栓塞、大出血、伤口并发症、感染和死亡等结局。

主要发现

  • 未发现磺达肝癸钠、依诺肝素或华法林在预防肺栓塞、深静脉血栓或静脉血栓栓塞方面优于阿司匹林的证据。
  • 未发现阿司匹林在安全性方面优于磺达肝癸钠、依诺肝素或华法林的证据。
  • 依诺肝素在出血方面与阿司匹林安全性相当。
  • 磺达肝癸钠在伤口并发症风险方面与阿司匹林安全性相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rates of venous thromboembolism in contemporary studies of primary total knee arthroplasty (TKA) have been reported to be as high as 3.5%. Although drug prophylaxis is effective, the best option among these regimens is not well established. The purpose of this study was to evaluate the comparative effectiveness and safety of aspirin, low-molecular-weight heparin, synthetic pentasaccharide factor Xa inhibitors, and vitamin K antagonist. METHODS: Data were from a US total joint replacement registry, with 30,499 patients receiving unilateral TKA from May 16, 2006, to December 31, 2013. Patients received either aspirin (324-325 mg daily), enoxaparin (40-60 mg daily), fondaparinux (2.5 mg daily), or warfarin (all doses) and were followed up 90 days postoperatively on several outcomes: deep vein thrombosis, pulmonary embolism, major bleeding, wound complications, infection, and death. RESULTS: There was no evidence that fondaparinux, enoxaparin, or warfarin were superior to aspirin in the prevention of pulmonary embolism, deep vein thrombosis, or venous thromboembolism or that aspirin was safer than these alternatives. However, enoxaparin was found to be as safe as aspirin with respect to bleeding, and fondaparinux was as safe as aspirin for risk of wound complications. CONCLUSION: Among TKA patients, we did not find evidence for decreased effectiveness or increased safety with use of aspirin, but enoxaparin had comparable safety to aspirin for bleeding and fondaparinux had comparable safety to aspirin for wound complications.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Cafri G, Paxton EW, Chen Y, et al. Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. J Arthroplasty. 2017. PMID: 28634095. doi:10.1016/j.arth.2017.05.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。